HDAC9 and multicystic dysplastic kidney: Their suitability is supported by prior studies [22], including our confirmation of VPA’s HDAC inhibitory activity (unpublished data; available upon request for peer review) and the literature linking prenatal ASM exposure to congenital anomalies such as multicystic dysplastic kidney (MCDK) [23], highlighting disrupted nephrogenesis as a key developmental concern.